How Tirzepatide Works
Dual-Receptor Mechanism
Unlike traditional GLP-1 agonists, Tirzepatide acts on both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual-pathway synergy enhances insulin sensitivity and appetite regulation more effectively than single-receptor drugs.
Clinical Results
Clinical programs like SURMOUNT have demonstrated significant efficacy, with participants in Phase 3 trials experiencing body weight reductions averaging ~20% over 72 weeks when combined with lifestyle interventions.
Beyond Weight Loss
Emerging research indicates broader metabolic and cardiovascular benefits, including improvements in:
- ✔ Cardiovascular health & blood pressure
- ✔ Obstructive Sleep Apnea (OSA) symptoms
- ✔ Insulin sensitivity and glycemic control
- ✔ Systemic inflammatory markers